Absci Corporation is a clinical-stage biopharmaceutical company that utilizes a data-first generative artificial intelligence platform to discover and develop biologic drugs. Headquartered in Vancouver, Washington, the company integrates AI with scalable wet-lab technologies to accelerate the creation of novel antibody therapeutics. Its proprietary Integrated Drug Creation platform aims to optimize multiple drug characteristics simultaneously, reducing the time and cost of traditional biologic drug discovery. Absci operates through collaborative partnerships with major pharmaceutical and technology companies, such as AstraZeneca and Memorial Sloan Kettering Cancer Center, while also advancing a wholly owned internal pipeline. Its preclinical and clinical programs focus on areas such as inflammatory bowel disease, immuno-oncology, and androgenic alopecia. By unifying in silico drug design with rapid biological validation, Absci seeks to engineer next-generation protein-based therapeutics.
